Cor Vasa 2010, 52(4):209-211

Snížení reziduálního vaskulárního rizika bude hlavní cíl preventivní kardiologie ve 21. století

Hana Rosolová
Centrum preventivní kardiologie, II. interní klinika, Fakultní nemocnice v Plzni a Lékařská fakulta Univerzity Karlovy v Praze, Český institut metabolického syndromu, o. p. s., Česká republika

Published: April 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosolová H. Snížení reziduálního vaskulárního rizika bude hlavní cíl preventivní kardiologie ve 21. století. Cor Vasa. 2010;52(4):209-211.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. International Diabetes Federation. Did you know - The human, social and economic impact of diabetes. http://www.idf.org/home/index.cfm?node=41.
    2. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. A condensed position paper by the Residual Risk Reduction Initiative (R3i). Diab Vasc Dis Res 2008;5:319-335. Go to original source... Go to PubMed...
    3. Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. A full position paper by the Residual Risk Reduction Initiative (R3i). Am J Cardiol 2008;102(10 Suppl):1K-34K. Go to original source... Go to PubMed...
    4. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278. Go to original source... Go to PubMed...
    5. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome. Results from the Prospective Cardiovascular Münster (PROCAM) Study. Int J Obes 2008;32:511-516. Go to original source... Go to PubMed...
    6. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008;156:112-119. Go to original source... Go to PubMed...
    7. Nordestgaard BG, Benn M, Schnohr, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308. Go to original source... Go to PubMed...
    8. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004;364:937-952. Go to original source... Go to PubMed...
    9. Retnakaran R, Cull CA, Thorne KI, UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes. UK Prospective Diabetes Study 74. Diabetes 2006;55:1832-1839. Go to original source... Go to PubMed...
    10. Tesfaye S, Chaturvedi N, Eaton SE, et al; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341-350. Go to original source... Go to PubMed...
    11. Jeon CY, Loken RP, Hu FB, et al. Physical activity of moderate intensity and risk of type 2 diabetes. A systematic review. Diabetes Care 2007;30:744-752. Go to original source... Go to PubMed...
    12. Rydén L, Standl E, Bartnik M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD): Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.
    13. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of Simvastatin plus Fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-468. Go to original source... Go to PubMed...
    14. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD Study): a randomised controlled trial. http://www.thelancet.com.doi:10.1016/S0140-6736(07)61607-9.
    15. ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. NEJM.org. 2010: 10.1056/NEJM0a1001282.
    16. Canner PL, Berge KG, Wenger NK, et al. Fifteen-year mortality in Coronary Drug Project: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255. Go to original source... Go to PubMed...
    17. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592. Go to original source... Go to PubMed...
    18. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517. Go to original source... Go to PubMed...
    19. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103:6682-6687. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes